The SYNERGY™ Biodegradable Program & EVOLVE Clinical Trials Ian T. Meredith Professor and Director of MonashHEART, Southern Health, Monash Medical Centre and Monash University Clayton, Victoria, Australia February 6, 2012 The SYNERGY stent is an investigational device. Not for sale.

Ian T Meredith, MD, PhD Honoraria: Abbott Vascular Boston Scientific Corporation Medtronic, Inc.

Desired Features of Next Generation DES Next Generation DES Desired Attributes SYNERGY™ Stent Attributes and Design Goals Acute Performance Stent & Delivery System Deliverable Visible Trackable Conformable PtCr Stent Platform Thinner Struts Modified Cell Geometry Improved Deliverability Efficacy Low Drug Load Good Clinical Outcomes Low TLR Low Clinical Symptom Recurrence Drug Load = PROMUS™/Xience™ Release kinetics similar to PROMUS™/Xience™ Safety Reduced Polymer Load Bioabsorbable Polymer BMS within 4mo Abluminal Polymer Coating Low Polymer Mass No Stent Thrombosis Shortened DAPT Requirement Safer for DAPT Interruption Presented by Ian Meredith, MBBS PhD, TCT 2011 The SYNERGY Stent System is an investigational device limited by law for investigational use. Not for sale.

Stent Design Progression: Platform Material SSTL CoCr / CoNi PtCr Architecture Strength Flexibility Coverage Optimization Closed Cell Open Cell Hybrid Strut Thickness 3rd Generation 2nd Generation 1st Generation 4th Generation The SYNERGY™ Stent is an investigational device and not for sale. The SYNERGY™ Stent is an investigational device and not for sale.

Platinum Chromium (PtCr) Stent Material Biocompatibility Radial Strength Bench Test Data Newtons/mm CoCr CoNi SSTL SSTL PtCr Flexibility Radiopacity PtCr CoCr CoNi SSTL SSTL Data on file. Stent Performance Summary April 2010. 2.50 mm Stents. PROMUS Element™ Stent n=15. TAXUS™ Liberté™ Stent n=10. Cypher™ Stent n=3. Endeavor™ Stent n=7. Xience V™ Stent n=10. Bench test results may not necessarily be indicative of clinical performance. Images taken by Boston Scientific. 3.0 mm Stents. 4.0 mm CU Phantom

PROMUS™ (Xience V™) Stent (n=762) PLATINUM Workhorse Less bail-out stenting with PtCr stents due to improved lesion coverage Overall Rate Cited Reason for Bail-out Stent P=0.004 P=0.36 P=0.01 P=0.06 Incidence Rate (%) PROMUS™ (Xience V™) Stent (n=762) PROMUS Element™ Stent (n=768) Presented by Gregg W. Stone, MD, ACC 2011. PROMUS Stent is a private-labeled Xience V Everolimus Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific Corporation. Xience V is a registered trademark of Abbott Cardiovascular Systems, Inc.

Stent Design Progression: Drug Delivery Anti-Restenotic Agents BMS DES Everolimus Polymer Coating Biostable Conformable Polymer Bioabsorbable Abluminal

Importance of Continued DES Innovation DAPT Considerations Patient Perspective Quality of life Side effects Other therapies Cost Piece of mind Physician Perspective Concerns with VLST Bleeding complications Non-compliance DAPT interruption DAPT responsiveness DES vs. BMS Delayed healing VLST Longer DAPT vs. BMS Discontinuation #1 ST Risk

SYNERGY™ Stent Abluminal Bioabsorbable Polymer Current Durable Polymer Bioabsorbable polymer (PLGA) Applied only to the abluminal surface (rollcoat) Thin strut PtCr Stent Current Durable Polymer Abluminal Bioabsorbable Polymer Durable Permanent Polymer + Drug 360° Around Stent PLGA Bioabsorbable Polymer + Everolimus on Abluminal Side of Stent Presented by Ian Meredith, MBBS, PhD at TCT 2011.  The SYNERGY™ Stent is an investigational device and not for sale.

Bioabsorbable Abluminal SYNERGY™ Stent Abluminal Bioabsorbable Polymer Thickness in Perspective 60 50-120µm 50 40 Micron (µm) 30 20 14µm 12-14µm 10 6-8µm 4µm Bioabsorbable Abluminal Polymer (Thickness) Red Cell (Diameter) TAXUS™ Liberté™ Polymer (Thickness) Neutrophil (Diameter) Human Hair (Thickness) The SYNERGY stent is an investigational device limited by law for investigational use. Not for sale.

SYNERGY™ Stent Designed for polymer resorption within 4 months Polymer Mass Remaining (%) Time (Days) PLGA mass assessed in explanted stent and adjacent tissue The SYNERGY stent is an investigational device limited by law for investigational use. Not for sale.

SYNERGY™ Stent Release Kinetics 60 50 In vitro KDR PROMUS Stent (in vivo) 40 In vivo release In vivo release Everolimus Cumulative Release (g) 30 SYNERGY Stent ½ Dose In vitro KDR 20 10 10 20 30 40 50 60 Time (days) Presented by Ian Meredith, MBBS, PhD at TCT 2010  The SYNERGY stent is an investigational device. Not for sale in the EEA. 12 12

SYNERGY™ Stent Design Attributes in Perspective Stent Strut Thickness (mm) Coating Approximate Coating Thickness (mm) Approximate Drug Load μg/mm SYNERGY™ 74 Abluminal 4 6 PROMUS™ / Xience™ 81 Conformal 8 Resolute Integrity™ 91 10 BioMatrix™ Flex 112 16 The SYNERGY stent is an investigational device limited by law for investigational use. Not for sale.

EVOLVE FHU (SYNERGY™ Stent) Study Design Patients with de novo native coronary lesions ≤28 mm in length, RVD ≥2.25 mm ≤3.5, %DS>50 (excluded LM disease, CTO, AMI or recent MI) Randomized 1:1:1 at 29 sites (EU, Australia, New Zealand) PROMUS Element™ N=98 SYNERGY N=94 SYNERGY ½ Dose N=99 Single-blind, noninferiority design Primary Clinical Endpoint: TLF (TV-CD, TV-MI, or TLR) at 30 days Primary Angiographic Endpoint: In-stent late loss at 6 months Presented by Ian Meredith, MBBS, PhD at TCT 2011.  The SYNERGY™ Stent is an investigational device and not for sale.

Sample Size & Power Calculation Primary Angiographic Endpoint: 6-month in-stent Late Loss Expected rate for both groups = 0.14 ± 0.47 mm* Non-inferiority margin (Δ) = 0.20 Test significance level () = 0.048 (1-sided) Power (1) = approximately 0.85 Expected rate of attrition = 20% N = 291 patients (97 per group at 1:1:1 ratio) Natfile06\depts\Clinical\Clinical Communications\Projects\IC\SYNERGY\Protocol\EVOLVE FHU\EVOLUTION FHU Protocol_Final_02Feb2010.doc Page 10 If the P value from the one-sided Student test is <0.048, it will be concluded that SYNERGY is non-inferior to PROMUS Element * From SPIRIT III (9-month endpoint)

EVOLVE Trial Support Ian Meredith Melbourne, Australia Stefan Verheye Co-Principal Investigators Ian Meredith Melbourne, Australia Stefan Verheye Antwerp, Belgium Core Labs Angio: CardioVascular Institute at BIDMC IVUS: MedStar Health Research Institute Clinical Events Committee Joseph Kannam (Chair) Germano DiSciascio Claude Hanet Goran Stankovic Data Monitoring Committee W. Douglas Weaver (Chair) David Parker Faxon Steven R. Bailey David J. Molitemo Jan G. P. Tijssen Adam Greenbaum

EVOLVE FHU (SYNERGY™ Stent) Target Lesion Failure 30 Days 6 Months P=0.49 P=1.00 P=0.25 P=0.72 Patients, % Patients, % PROMUS Element™ SYNERGY SYNERGY ½ Dose PROMUS Element SYNERGY SYNERGY ½ Dose Intent-to-treat; P values are versus PROMUS Element (Fisher exact test) Presented by Ian Meredith, MBBS, PhD at TCT 2011.  The SYNERGY™ Stent is an investigational device and not for sale.

EVOLVE FHU (SYNERGY™ Stent) Late Loss at 6 Months Difference and 95.2% UCB Noninferiority Threshold P=0.19* P=0.56* SYNERGY P<0.001 Difference (SYNERGY – PROMUS Element) Late loss, mm SYNERGY ½ Dose P<0.001 PROMUS Element™ SYNERGY SYNERGY ½ Dose Noninferiority is proven because the upper 95.2% confidence bound of the difference in 6-month late loss is <0.20 for both SYNERGY stents Intent-to-treat; *P values for superiority comparison Presented by Ian Meredith, MBBS, PhD at TCT 2011.  The SYNERGY™ Stent is an investigational device and not for sale.

EVOLVE FHU (SYNERGY™ Stent) Revascularization and ST at 6 Months PROMUS Element™ SYNERGY ½ Dose SYNERGY All P=N.S. Patients, % TVR TLR Non-TLR TVR Stent Thrombosis Intent-to-treat; P values are versus PROMUS Element (Fisher exact test) Presented by Ian Meredith, MBBS, PhD at TCT 2011.  The SYNERGY™ Stent is an investigational device and not for sale.

Clinical Trial Plan for the SYNERGY™ Stent EVOLVE Clinical Trials Clinical Trial Plan for the SYNERGY™ Stent EVOLVE FHU 291 patients Control Device PROMUS Element™ Primary Endpoint 30D TLF 6M Late Loss TCT 2011 EVOLVE II 1684 patients Control Device PROMUS Element™ Plus Primary Endpoint 12M TLF 2014 Planned Pre-Approval EVOLVE QCA/PK EVOLVE China EVOLVE India Post-Approval EVOLVE DAPT The SYNERGY stent is an investigational device limited by law for investigational use. Not for sale. 20 20

Where Will the SYNERGY™ Stent Sit in the DES Landscape? Concerns with DES Late ST DAPT Compliance DAPT Interruption SYNERGY™ Stent Design Reduced Polymer Load Minimal Drug Burden Short Term Polymer Exposure Desired Outcomes Improve late events Reduce DAPT duration Reduce risk w/DAPT interruption Although DES have significantly improved restenosis outcomes compared with BMS, issues such as late ST and DAPT compliance remain a concern Minimizing polymer and/or drug burden may be key to improving late events or reducing risk associated with DAPT interruption for DES The next generation SYNERGY stent utilizes the proven PtCr stent platform, a proven dose of everolimus, and a bioabsorbable polymer designed to leave a bare metal stent within 4 months of implantation This stent is currently being evaluated in the EVOLVE randomized, controlled clinical trial BSC data on file. The SYNERGY stent is an investigational device limited by law for investigational use. Not for sale.

Thank You

DES Drug and Polymer Weight SYNERGY™ Stent* BioMatrix™ Stent Xience ™ (PROMUS™) Stent BVS Stent + Coating Bare-Metal Stent ½ X Dose 1X Dose // l l l l l l l l l l l 0 100 200 300 400 500 600 700 7,700 7,800 7,900 Coating Weight (µg, 16 mm Stent) Data on file Boston Scientific Corporation. Coating weights for BioMatrix is estimates for a 16mm stent based on published coat weights for 3.0x18mm stents. The SYNERGY stent is an investigational device limited by law to investigational use. Not for sale. 23 23 23

EVOLVE FHU (SYNERGY™ Stent) Baseline Demographics PROMUS Element™ N=98 SYNERGY N=94 P value SYNERGY ½ Dose N=99 P value Age, years 62.1 ± 10.0 64.9 ± 11.0 0.07 62.9 ± 10.2 0.61 Male 79.6% 69.9% 0.12 69.7% 0.11 Hypertension 69.4% 61.3% 0.24 71.7% 0.72 Hyperlipidemia 70.4% 68.5% 0.77 72.4% 0.75 Diabetes* 22.4% 17.2% 0.36 18.2% 0.46 Insulin-treated 8.2% 6.5% 0.65 4.0% 0.23 Current smoker 27.8% 21.7% 0.33 20.6% Prior MI 34.4% 32.3% 0.76 34.7% 0.96 Unstable angina 21.1% 22.6% 0.80 30.6% 0.13 Intent-to-treat; P values are versus PROMUS Element; *medically treated Presented by Ian Meredith, MBBS, PhD at TCT 2011.  The SYNERGY™ Stent is an investigational device and not for sale. 24

SYNERGY™ Stent Physical and Chemical Changes Drug released over 3 months Polymer resorbed within 4 months Schematic Drug Burst release Sustained release Drug release is completed Polymer Hydration & polymer molecular weight reduction begins Significant reduction in molecular weight & polymer absorption begins Molecular weight continues to drop & remaining polymer is absorbed Vessel Wall Vessel Wall Vessel Wall Lactic & Glycolic Acid H2O Lactic & Glycolic Acid Everolimus H2O H2O Everolimus Stent Surface Stent Surface Stent Surface BSC data on file. The SYNERGY stent system is an investigational device limited by law for investigational use. Not for sale. 25 25